22 Aug 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Oramed Pharmaceuticals initiated patient recruitment for a new clinical trial of its orally ingestible insulin capsule,ORMD-0801, for patients with type 1 diabetes mellitus (T1DM) in Israel.
Earlier clinical studies have shown that ORMD-0801 administered to T1DM patients just prior to a meal, effectively kept their blood sugar levels stable. The results of one such trial were published earlier this year in the international, peer-reviewed journal PLOS ONE.
The research article is titled, 'Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study'.
Mr Nadav Kidron, CEO, Oramed, "We are very excited to continue our development of ORMD-0801 for this high-need indication. We have been encouraged by our successful T1DM trials to date and we look forward to the commencement of this study."